I. Cohen et al., Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients, J CLIN PATH, 52(4), 1999, pp. 278-282
Citations number
43
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Aims-To evaluate whether endometrial pathology is more likely to be diagnos
ed in gynaecologically symptomatic rather than in gynaecologically asymptom
atic postmenopausal breast cancer patients with tamoxifen treatment; and to
evaluate the possible influence of various clinical factors on the inciden
ce of endometrial pathology.
Methods-Endometrial histological findings, transvaginal ultrasonographic en
dometrial thickness, demographic characteristics, health habits, and risk f
actors for endometrial cancer were compared between 14 gynaecologically sym
ptomatic (group I) and 224 gynaecologically asymptomatic (group II) postmen
opausal breast cancer patients with tamoxifen treatment.
Results-Overall, 28.6% of the study population had endometrial pathology. T
he incidence of overall positive endometrial histological findings was sign
ificantly higher in group I than in group II (92.9% v 24.6%, p < 0.0001). A
trophic endometrium was more common in group II than in group I (75.3% v 7.
1%, p < 0.0001). Most other endometrial pathology was significantly more co
mmon in group I than in group UI (endometrial hyperplasia, 35.7% v 5.6%, p
< 0.0001; endometrial polyps, 35.7% v 13.4%, p < 0.0111; endometrial carcin
oma, 21.5% v 0.9%, p < 0.0001). Endometrial pathology appeared considerably
later ia the gynaecologically asymptomatic patients than in gynaecological
ly symptomatic patients (p = 0.0002). Vaginal bleeding or spotting occurred
exclusively in group I. The incidence of endometrial pathology in the enti
re study population Mras consistent with that reported elsewhere, and highe
r than that reported for healthy postmenopausal women.
Conclusions-Endometrial pathology is more likely to be diagnosed In gynaeco
logically symptomatic postmenopausal breast cancer patients with tamoxifen
treatment, and after a shorter duration of time, than in gynaecologically a
symptomatic patients.